Purpose Oral temozolomide is approved in many countries for malignant glioma and for
melanoma in some countries outside the USA. This study evaluated the exposure equivalence …

… Krishna, AbuTarif, and Angulo declare stock ownership in Schering-Plough. Dr. Cornely
is supported by the German Federal Ministry of Research and Education (BMBF grant …

Trastuzumab deruxtecan (T‐DXd) is a HER2‐targeting antibody‐drug conjugate composed
of a novel enzyme‐cleavable linker and membrane‐permeable topoisomerase I inhibitor …

The pharmacokinetics, pharmacodynamics, safety, and tolerability of BMS-932481, a γ-secretase
modulator (GSM), were tested in healthy young and elderly volunteers after single and …

Trastuzumab deruxtecan (DS‐8201) is a human epidermal growth factor receptor 2 (HER2)–targeting
antibody–drug conjugate with a novel enzyme‐cleavable linker, a topoisomerase I …

Objective: The relationship between patient characteristics and posaconazole exposures
was evaluated in a population pharmacokinetic (PK) model using trial data from neutropenic …

… was a single-center, open-label, single-sequence five-period study open to healthy volunteers
between the ages of 18 and 45 years, with a body mass index between 18 and 32 kg/m 2 …

The amyloid-β peptide (Aβ)—in particular, the 42–amino acid form, Aβ1-42—is thought to
play a key role in the pathogenesis of Alzheimer’s disease (AD). Thus, several therapeutic …

This study evaluated the benefit/risk of trastuzumab deruxtecan (T‐DXd) 6.4 mg/kg in
patients with human epidermal growth factor receptor 2 (HER2)‐positive gastric cancer using …

… LH would like to thank her mentors who helped her transition into clinical pharmacology and
pharmacometrics: Dr Malaz AbuTarif, Dr Craig Thalhauser, Dr Tushar Garimella, Dr Phyllis …